CD16 Fc receptor levels were decreased both for MV-BiKE and MV + vBiKE treatment, which was most pronounced for conditions with tumor-specific, CEA-targeting BiKEs (Fig. 4C(ii), S6B(ii)). Here, FCGR3A is linked to neoplasm.